Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Exploiting the activity of the ALDH enzyme to develop highly selective drugs for cancer stem cells

Project description

An innovative approach for targeting cancer stem cells

Accumulating evidence reinforces the theory that cancer is developed and maintained by a subpopulation of cancer cells with stem cell properties. These cancer stem cells (CSCs) are typically in a quiescent state, making them resistant to standard therapies and responsible for disease relapse. The ERC-funded SeleCStem project aims to develop innovative strategies to target CSCs effectively by exploiting the enzyme aldehyde dehydrogenase (ALDH), which is overexpressed in CSCs across various cancers. The research team will harness the enzyme’s activity to selectively release drugs within CSCs and combine it with light-mediated inhibition of ALDH in tumours.

Objective

Despite huge advances in cancer treatment, resistance to chemotherapy is still common. It is now well established that a small population of cells named cancer stem cells (CSCs) have high tumorigenicity and are able to initiate and maintain a tumour. CSCs usually remain in a quiescent state that is not affected by standard chemotherapy; thus, they are often responsible for treatment resistance and relapse. There is a clear need to find effective treatments against CSCs to fully eradicate the tumour. However, the close similarities of CSCs to healthy stem cells hinders the identification of selective drugs.
In the last years, new drug modalities are emerging to provide therapeutic options for challenging targets and diseases, expanding the drug discovery landscape. In line with these trends, SeleCStem aims to develop innovative chemical biology strategies to target CSCs in a safe and effective manner. It will exploit the activity of the enzyme ALDH, which is overexpressed in CSCs of many cancer types, to obtain selective drugs using three orthogonal strategies: we will use the oxidoreductase activity of ALDH to trigger the selective (1) accumulation or (2) release of drugs inside CSCs and (3) use external light to inhibit ALDH only in the tumour area. Successful strategies will be combined at the end of the project to overcome potential limitations of the individual approaches, hence massively increasing the drugs’ selectivity and efficacy. We will design these molecules with the aid of docking studies, synthesise them, and assess their ALDH- or light-triggered activation in purified enzyme assays and in CSC spheres.
Overall, we will develop the proof of concept of unprecedented approaches to eliminate CSCs with outstanding precision, thus overcoming some of the limitations of conventional small molecules going beyond state-of-the-art chemical biology. Our ultimate goal is to contribute to improve cancer treatment and increase complete remission rates.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC - HORIZON ERC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-STG

See all projects funded under this call

Host institution

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Net EU contribution
€ 1 499 948,00
Address
CALLE SERRANO 117
28006 Madrid
Spain
Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Links
Total cost
€ 1 499 948,00

Beneficiaries (1)